Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA

V. Krchnak, Josef Vagner, A. Suchankova, M. Krcmar, L. Ritterova, V. Vonka

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Nine overlapping peptides (20 amino acid) covering the entire sequence of early antigen E7 of human papillomavirus type 16 (HPV-16) were synthesized and tested as antigens with human sera in ELISA. Five of these peptides (no. 1 to 5 counting from the N terminus of the E7 protein) reacted with a pool of sera from HPV-16-infected individuals (as determined by molecular hybridization with their biopsy specimens); one (no. 5) was also reactive with pools of HPV-18- and HPV-6- or 11-infected individuals. Sera from 24 patients with cervical intraepithelial neoplasia (CIN) and from 29 invasive cervical carcinoma (INCA) patients were tested for the presence of antibodies reactive with peptides, no. 1 to 4 covering amino acids 1 to 50 and with peptide no. 5 covering amino acids 41 to 60. Only one of the sera from CIN patients was reactive with peptides no. 1 (amino acids 1 to 20) and no. 4 (amino acids 31 to 50). However, the majority of these sera reacted with peptide no. 5. The occurrence of this antibody was only slightly less frequent in sera from healthy subjects compared to CIN patients. On the other hand, sera from the INCA patients were reactive with the peptides no. 1 to 3 more frequently than the sera from matched control subjects. Positive reactions of sera from INCA patients were most frequently seen with no. 2; 24% of these sera but only 7% of the controls were reactive with no. 2 peptide. The present data suggest that no. 1 to 3 are HPV-16-specific, whereas no. 5 is broadly cross-reactive.

Original languageEnglish (US)
Pages (from-to)2719-2724
Number of pages6
JournalJournal of General Virology
Volume71
Issue number11
StatePublished - 1990
Externally publishedYes

Fingerprint

Human papillomavirus 16
Enzyme-Linked Immunosorbent Assay
Antigens
Peptides
Serum
Cervical Intraepithelial Neoplasia
Amino Acids
Carcinoma
Human papillomavirus 11
Human papillomavirus 6
Human papillomavirus 18
Antibodies
Healthy Volunteers
Biopsy

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Krchnak, V., Vagner, J., Suchankova, A., Krcmar, M., Ritterova, L., & Vonka, V. (1990). Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. Journal of General Virology, 71(11), 2719-2724.

Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. / Krchnak, V.; Vagner, Josef; Suchankova, A.; Krcmar, M.; Ritterova, L.; Vonka, V.

In: Journal of General Virology, Vol. 71, No. 11, 1990, p. 2719-2724.

Research output: Contribution to journalArticle

Krchnak, V, Vagner, J, Suchankova, A, Krcmar, M, Ritterova, L & Vonka, V 1990, 'Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA', Journal of General Virology, vol. 71, no. 11, pp. 2719-2724.
Krchnak, V. ; Vagner, Josef ; Suchankova, A. ; Krcmar, M. ; Ritterova, L. ; Vonka, V. / Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. In: Journal of General Virology. 1990 ; Vol. 71, No. 11. pp. 2719-2724.
@article{6b82f1c394c94f7c9aaf9ba792467811,
title = "Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA",
abstract = "Nine overlapping peptides (20 amino acid) covering the entire sequence of early antigen E7 of human papillomavirus type 16 (HPV-16) were synthesized and tested as antigens with human sera in ELISA. Five of these peptides (no. 1 to 5 counting from the N terminus of the E7 protein) reacted with a pool of sera from HPV-16-infected individuals (as determined by molecular hybridization with their biopsy specimens); one (no. 5) was also reactive with pools of HPV-18- and HPV-6- or 11-infected individuals. Sera from 24 patients with cervical intraepithelial neoplasia (CIN) and from 29 invasive cervical carcinoma (INCA) patients were tested for the presence of antibodies reactive with peptides, no. 1 to 4 covering amino acids 1 to 50 and with peptide no. 5 covering amino acids 41 to 60. Only one of the sera from CIN patients was reactive with peptides no. 1 (amino acids 1 to 20) and no. 4 (amino acids 31 to 50). However, the majority of these sera reacted with peptide no. 5. The occurrence of this antibody was only slightly less frequent in sera from healthy subjects compared to CIN patients. On the other hand, sera from the INCA patients were reactive with the peptides no. 1 to 3 more frequently than the sera from matched control subjects. Positive reactions of sera from INCA patients were most frequently seen with no. 2; 24{\%} of these sera but only 7{\%} of the controls were reactive with no. 2 peptide. The present data suggest that no. 1 to 3 are HPV-16-specific, whereas no. 5 is broadly cross-reactive.",
author = "V. Krchnak and Josef Vagner and A. Suchankova and M. Krcmar and L. Ritterova and V. Vonka",
year = "1990",
language = "English (US)",
volume = "71",
pages = "2719--2724",
journal = "Journal of General Virology",
issn = "0022-1317",
publisher = "Society for General Microbiology",
number = "11",

}

TY - JOUR

T1 - Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA

AU - Krchnak, V.

AU - Vagner, Josef

AU - Suchankova, A.

AU - Krcmar, M.

AU - Ritterova, L.

AU - Vonka, V.

PY - 1990

Y1 - 1990

N2 - Nine overlapping peptides (20 amino acid) covering the entire sequence of early antigen E7 of human papillomavirus type 16 (HPV-16) were synthesized and tested as antigens with human sera in ELISA. Five of these peptides (no. 1 to 5 counting from the N terminus of the E7 protein) reacted with a pool of sera from HPV-16-infected individuals (as determined by molecular hybridization with their biopsy specimens); one (no. 5) was also reactive with pools of HPV-18- and HPV-6- or 11-infected individuals. Sera from 24 patients with cervical intraepithelial neoplasia (CIN) and from 29 invasive cervical carcinoma (INCA) patients were tested for the presence of antibodies reactive with peptides, no. 1 to 4 covering amino acids 1 to 50 and with peptide no. 5 covering amino acids 41 to 60. Only one of the sera from CIN patients was reactive with peptides no. 1 (amino acids 1 to 20) and no. 4 (amino acids 31 to 50). However, the majority of these sera reacted with peptide no. 5. The occurrence of this antibody was only slightly less frequent in sera from healthy subjects compared to CIN patients. On the other hand, sera from the INCA patients were reactive with the peptides no. 1 to 3 more frequently than the sera from matched control subjects. Positive reactions of sera from INCA patients were most frequently seen with no. 2; 24% of these sera but only 7% of the controls were reactive with no. 2 peptide. The present data suggest that no. 1 to 3 are HPV-16-specific, whereas no. 5 is broadly cross-reactive.

AB - Nine overlapping peptides (20 amino acid) covering the entire sequence of early antigen E7 of human papillomavirus type 16 (HPV-16) were synthesized and tested as antigens with human sera in ELISA. Five of these peptides (no. 1 to 5 counting from the N terminus of the E7 protein) reacted with a pool of sera from HPV-16-infected individuals (as determined by molecular hybridization with their biopsy specimens); one (no. 5) was also reactive with pools of HPV-18- and HPV-6- or 11-infected individuals. Sera from 24 patients with cervical intraepithelial neoplasia (CIN) and from 29 invasive cervical carcinoma (INCA) patients were tested for the presence of antibodies reactive with peptides, no. 1 to 4 covering amino acids 1 to 50 and with peptide no. 5 covering amino acids 41 to 60. Only one of the sera from CIN patients was reactive with peptides no. 1 (amino acids 1 to 20) and no. 4 (amino acids 31 to 50). However, the majority of these sera reacted with peptide no. 5. The occurrence of this antibody was only slightly less frequent in sera from healthy subjects compared to CIN patients. On the other hand, sera from the INCA patients were reactive with the peptides no. 1 to 3 more frequently than the sera from matched control subjects. Positive reactions of sera from INCA patients were most frequently seen with no. 2; 24% of these sera but only 7% of the controls were reactive with no. 2 peptide. The present data suggest that no. 1 to 3 are HPV-16-specific, whereas no. 5 is broadly cross-reactive.

UR - http://www.scopus.com/inward/record.url?scp=0025012316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025012316&partnerID=8YFLogxK

M3 - Article

C2 - 2174961

AN - SCOPUS:0025012316

VL - 71

SP - 2719

EP - 2724

JO - Journal of General Virology

JF - Journal of General Virology

SN - 0022-1317

IS - 11

ER -